AI evidence summary · MVP
Magnesium for Constipation
AI preliminary evidence assessment
BB 級｜AI 整體初步評級
This preliminary assessment is currently available in Traditional Chinese.
Exact question對有慢性便秘的成人，口服單方鎂鹽是否改善排便、治療反應或便秘症狀，並有哪些不良反應？
兩項四週小型隨機試驗支持氧化鎂改善慢性便秘的整體反應、排便與生活品質，但結果不能直接外推至檸檬酸鎂或氫氧化鎂；高齡者與腎功能較差者的高血鎂風險需分開考量。
Why this assessment was given
- 氧化鎂提高整體症狀改善反應率，增加自發性排便（SBM），並改善日本版便祕患者生活品質量表（JPAC-QOL）及便秘評分；但整體完全自發性排便（CSBM）反應率與安慰劑無顯著差異，部分腹部症狀亦無組間差異。
Limitations affecting this assessment
- 直接療效證據主要來自兩項日本小型、短期（4週）氧化鎂試驗，合計僅94名隨機分派至氧化鎂或安慰劑，且93%為女性，限制精確度、長期推論與族群外推。
- 2019年試驗僅34人、單中心且排除一名未完成者；基線結腸轉運、便秘評分及生活品質不平衡，並出現完整自發排便反應未達顯著的結果。
- 2021年試驗目前僅有摘要資料，無法充分核對隨機化、偏倚、輕中度不良事件、劑量調整及詳細停藥資料。
- AGA/ACG僅對氧化鎂提出條件式建議，整體證據確定性評為極低；其重複期刊版本不得視為獨立支持。
- 氫氧化鎂證據來自64名便秘高齡長住院者的交叉研究，慢性便秘診斷與持續時間不清；兩篇出版品屬同一隊列，不能重複計數。
- 氫氧化鎂研究中2人血鎂超過1.25 mmol/L；氧化鎂觀察研究亦顯示低腎功能高齡者血鎂較高，但這些安全資料規模小、非隨機或來源受限。
- 缺乏檸檬酸鎂治療成人慢性便秘的直接證據；此為證據缺口，不能解讀為無效。
- 沒有足夠的長期療效、腹瀉、停藥、罕見嚴重高血鎂或其他嚴重不良事件資料；部分個案與安全紀錄亦僅有題名或摘要。
- 2025年氧化鎂與elobixibat的研究為非隨機觀察性比較，且偏重排便慾、直腸感覺與轉運等輔助指標，不能提供穩健的相對療效結論。
- 直接療效試驗僅評估氧化鎂1.5 g每日、療程四週，尚無同等直接證據支持其他鎂鹽或長期使用。
- 高血鎂安全資料來自非隨機高齡門診比較，未報確切事件數與暴露期間。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
4 週氧化鎂提高整體症狀改善反應率，增加SBM，並改善JPAC-QOL及便秘評分；但整體CSBM反應率與安慰劑無顯著差異，部分腹部症狀亦無組間差異。
Applicability assessment: 成人慢性功能性便秘的安慰劑對照試驗。
- Population
- 34名輕至中度慢性功能性便祕女性
- Intervention
- 氧化鎂1.5 g每日
- Comparator
- 安慰劑
- Outcome
- 整體症狀改善、排便與生活品質
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- 氧化鎂1.5 g每日
Source excerpt: Compared to the response rate of 25.0% for overall symptom improvement in the placebo group, that with magnesium oxide (MgO) was significantly higher at 70.6%.View source
Main result 2
4 週氧化鎂相較安慰劑提高整體改善反應率，並顯著改善SBM、CSBM及便秘相關生活品質；摘要僅提供部分效應量與P值。
Applicability assessment: 成人慢性特發性便秘的安慰劑對照試驗。
- Population
- 90名慢性特發性便祕成人
- Intervention
- 氧化鎂1.5 g每日
- Comparator
- 安慰劑；另有番瀉葉組
- Outcome
- 整體改善、自發排便、完全自發排便與生活品質
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- 氧化鎂1.5 g每日
Source excerpt: The response rate for overall improvement was 11.7% in the placebo group, 69.2% in the senna group, and 68.3% in the MgO group (P <View source
Safety finding 3
23名氧化鎂使用者中出現高血鎂，但摘要未報確切事件人數；症狀在兩組皆有且組間無顯著差異。G4腎功能類別的血清鎂最高，但原文同時以3.0 mg/L呈現，與前述mg/dL單位可能不一致，應保留此來源不確定性。
Applicability assessment: 高齡便秘門診患者提供安全訊號，但未確認慢性便秘且屬非隨機比較。
- Population
- 44名高齡門診患者，其中23名因便祕使用氧化鎂
- Intervention
- 每日口服氧化鎂
- Comparator
- 未使用氧化鎂的高齡對照
- Outcome
- 血清鎂、高血鎂與腎功能
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: Hypermagnesemia (>2.6 mg/dL) was noted only in the MgO group.View source
Additional finding 4
64名高齡長住院便秘患者的交叉研究比較氫氧化鎂與膨脹性瀉劑；慢性便秘診斷與持續時間無法由摘要確認。
Applicability assessment: 慢性便秘適用性無法確認。
- Population
- 64名高齡長住院便祕患者
- Intervention
- 氫氧化鎂
- Comparator
- 膨脹性瀉劑
- Outcome
- 排便與安全背景
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: Sixty-four geriatric long-stay patients aged 65 years or older participated in the trial.View source
Additional finding 5
另一篇報告描述同一批64名高齡長住院便秘患者的營養與礦物質結果，不應重複計為獨立研究群體。
Applicability assessment: 疑與另一報告為同一隊列。
- Population
- 64名高齡長住院便祕患者
- Intervention
- 氫氧化鎂
- Comparator
- 膨脹性瀉劑
- Outcome
- 營養與礦物質背景
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: 64 constipated, elderly long-stay patients, 55 of whom were receiving diuretics.View source
Additional finding 6
2025年研究以真實世界觀察設計比較氧化鎂與Elobixibat的排便慾、直腸感覺及結腸轉運。
Applicability assessment: 非隨機且結果偏重生理指標。
- Population
- Rome IV慢性便祕患者
- Intervention
- 氧化鎂
- Comparator
- Elobixibat
- Outcome
- 排便慾、直腸感覺與結腸轉運
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: This was a prospective, observational study conducted in real-world clinical practice.View source
Additional finding 7
AGA與ACG成人慢性特發性便秘指引對氧化鎂提出條件式建議，並整理兩項日本安慰劑對照試驗。
Applicability assessment: 指引整理證據但不增加參與者。
- Population
- 成人慢性特發性便祕
- Intervention
- 氧化鎂
- Comparator
- 多種藥物治療
- Outcome
- 指引建議與證據確定性
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: Conditional recommendations were made for the use of fiber, lactulose, senna, magnesium oxide, and lubiprostone.View source
Sources consulted
- Comparison of the effects of magnesium hydroxide and a bulk laxative on lipids, carbohydrates, vitamins A and E, and minerals in geriatric hospital patients in the treatment of constipation. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:59:41.450908Z
- Relationship between renal function and serum magnesium concentration in elderly outpatients treated with magnesium oxide. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:59:41.450908Z
- Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:59:41.450908Z
- A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. Full text · 2026-09-19T12:59:41.450908Z
- Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. Abstract only · 2026-09-19T12:59:41.450908Z
- American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Context source; not counted as an included human-result report Full text · 2026-09-19T12:59:41.450908Z
- Comparison of the Effectiveness of Magnesium Oxide and Elobixibat on Improving Rectal Sensitivity and Colonic Transit Time in Patients With Chronic Constipation: An Observational Study. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:59:41.450908Z
Reading and assessment notes
This is an AI preliminary assessment, not expert review or formal GRADE. Read the method and common limitations.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
對有慢性便祕的成人，口服單方鎂鹽是否改善排便、治療反應或便祕症狀，並有哪些不良反應？
Searched：2026-09-19T12:59:41.450908Z · Databases：PubMed
320 records identified; 320 screened; 2 reports from 2 unique study populations included.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文，完整偏倚風險與次要結果評讀受限。
- 本次檢索限於 PubMed 與已取得全文，未進行所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through：2026-09-19 · Generated：2026-09-19T13:51:00.994480+00:00
Retrieved 320 records · Screened 320 · Included 2 reports · Omitted 318
Run：magnesium-constipation-verified-v5
codex_cli / gpt-5.6-sol / problem-search-source-bound-l2+l11-v1
{
"included": 2,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 318,
"retrieved": 320,
"screened": 320
} sha256:4cc4dc2a6093f2da167a42c1d83934d260be59a437df5b7bcad9e7482ae62624